Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status

Background: Skeletal muscle weakness is assumed to be present in patients with sarcoidosis but has never been reported in a consecutive group of patients. Moreover, its relationship with previously observed exercise intolerance and reduced health status has never been studied in these patients. Methods: Pulmonary function, skeletal and respiratory muscle forces, peak and functional exercise capacity, health status, and the circulating levels of inflammatory and anabolic markers were determined in 25 patients with sarcoidosis who complained of fatigue (15 men) and in 21 healthy subjects (13 men). Results: Patients with sarcoidosis had lower respiratory and skeletal muscle forces, reduced exercise capacity and health status, higher anxiety and depression scores, and higher circulating levels of tumour necrosis factor-α than healthy subjects (all p⩽0.01). Its soluble receptor p75 tended to be higher (p = 0.04). Circulating levels of interleukin (IL)-6, IL-8, insulin-like growth factor I and its binding protein 3 were not significantly different between the two groups. Skeletal muscle weakness was related to exercise intolerance, depression, and reduced health status in patients with sarcoidosis, irrespective of age, sex, body weight and height (p⩽0.05). Quadriceps peak torque was inversely related to fatigue but not to the circulating levels of inflammatory or anabolic markers. The mean daily dose of corticosteroids received in the 6 month period before testing was related to quadriceps peak torque only in patients who received oral corticosteroids. Conclusion: Skeletal muscle weakness occurs in patients with sarcoidosis who complain of fatigue and is associated with reduced health status and exercise intolerance.

[1]  A. Chaudhuri,et al.  Fatigue in neurological disorders , 2004, The Lancet.

[2]  C. Gallagher,et al.  Corticosteroids and skeletal muscle function in cystic fibrosis. , 2003, Journal of applied physiology.

[3]  M. Decramer,et al.  CHRONIC OBSTRUCTIVE PULMONARY DISEASE Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I , 2003 .

[4]  Cynthia D. Brown,et al.  The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. , 2003, American journal of respiratory and critical care medicine.

[5]  M. Drent.  Sarcoidosis: benefits of a multidisciplinary approach. , 2003, European journal of internal medicine.

[6]  M. Ziegenhagen,et al.  The cytokine network in sarcoidosis and its clinical relevance , 2003, Journal of internal medicine.

[7]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[8]  C. Rochester,et al.  Randomised controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease , 2002, Thorax.

[9]  J. Thissen,et al.  Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. , 2002, American journal of physiology. Endocrinology and metabolism.

[10]  M. Decramer,et al.  Resistance versus endurance training in patients with COPD and peripheral muscle weakness , 2002, European Respiratory Journal.

[11]  B. Wallaert,et al.  Impaired exercise response in sarcoid patients with normal pulmonary functio. , 2002, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  G. Schuler,et al.  Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[13]  P. Rosseel,et al.  Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. , 2002, British journal of anaesthesia.

[14]  S. Ward,et al.  Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD) , 2002, Thorax.

[15]  P. Jones,et al.  Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. , 2002, JAMA.

[16]  A. Coats,et al.  Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[17]  K. Schulz,et al.  An overview of clinical research: the lay of the land , 2002, The Lancet.

[18]  A. Medinger,et al.  Sarcoidosis: the value of exercise testing. , 2002, Chest.

[19]  G. McLennan,et al.  Clinical characteristics of patients in a case control study of sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[20]  J. Bavaria,et al.  Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. , 2001, Chest.

[21]  F. Graziano,et al.  Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. , 2001, Journal of immunological methods.

[22]  S. Anker,et al.  High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. , 2001, Cytokine.

[23]  A. Mohan,et al.  Clinical characteristics, pulmonary function abnormalities and outcome of prednisolone treatment in 106 patients with sarcoidosis. , 2001, The Journal of the Association of Physicians of India.

[24]  U. Tan,et al.  Isokinetic Muscle Performance in Major Depressive Disorder: Alterations by Antidepressant Therapy , 2001, The International journal of neuroscience.

[25]  M. Decramer.  The respiratory rehabilitation division of the University Hospital Gasthuisberg, Leuven, Belgium , 2001 .

[26]  C. Rand,et al.  Depression in sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[27]  A. Steensberg,et al.  Exercise and cytokines with particular focus on muscle-derived IL-6. , 2001, Exercise immunology review.

[28]  N. McGregor,et al.  Exercise capacity in chronic fatigue syndrome. , 2000, Archives of internal medicine.

[29]  P. White,et al.  Strength and physiological response to exercise in patients with chronic fatigue syndrome , 2000, Journal of neurology, neurosurgery, and psychiatry.

[30]  G. Van den Berghe,et al.  A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  G. Raghu,et al.  Assessment of health-related quality of life in patients with interstitial lung disease. , 1999, Chest.

[32]  M. Decramer,et al.  Six minute walking distance in healthy elderly subjects. , 1999, The European respiratory journal.

[33]  D. Papanicolaou,et al.  Circadian interleukin-6 secretion and quantity and depth of sleep. , 1999, The Journal of clinical endocrinology and metabolism.

[34]  E. Wouters,et al.  Association of fatigue with an acute phase response in sarcoidosis. , 1999, The European respiratory journal.

[35]  A. Pestronk,et al.  Clinical correlates of granulomas in muscle , 1998, Journal of Neurology.

[36]  P. Zipfel,et al.  Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. , 1998, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[37]  N. MacIntyre,et al.  Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. , 1998, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[38]  Deremee Ra.  Dysphoria and sarcoidosis. , 1998 .

[39]  E. Wouters,et al.  Quality of life and depressive symptoms in patients suffering from sarcoidosis. , 1998, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[40]  R. Deremee.  Dysphoria and sarcoidosis. , 1998, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[41]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[42]  E. Wouters,et al.  Relationship between respiratory muscle function and quality of life in sarcoidosis. , 1997, The European respiratory journal.

[43]  P. Poole‐Wilson,et al.  The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. , 1997, European heart journal.

[44]  G. Guyatt,et al.  Assessing the minimal important difference in symptoms: a comparison of two techniques. , 1996, Journal of clinical epidemiology.

[45]  M. Decramer,et al.  Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[46]  S. Lareau,et al.  Functional status instruments: outcome measure in the evaluation of patients with chronic obstructive pulmonary disease. , 1996, Heart & lung : the journal of critical care.

[47]  M. Decramer,et al.  Peripheral muscle weakness contributes to exercise limitation in COPD. , 1996, American journal of respiratory and critical care medicine.

[48]  G. Campbell,et al.  Muscle weakness, fatigue, and joint pain in a 52-year-old woman. , 1995, Chest.

[49]  A. Teirstein,et al.  Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. , 1995, Chest.

[50]  M. Decramer,et al.  Corticosteroids contribute to muscle weakness in chronic airflow obstruction. , 1994, American journal of respiratory and critical care medicine.

[51]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[52]  M. Kraft,et al.  Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. , 1992, Chest.

[53]  N. Jones,et al.  Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation. , 1992, Thorax.

[54]  A. Cilursu,et al.  Sarcoidosis presenting as acute myositis. Report and review of the literature. , 1988, The Journal of rheumatology.

[55]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[56]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[57]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[58]  L. Makrides,et al.  Normal standards for an incremental progressive cycle ergometer test. , 1985, The American review of respiratory disease.

[59]  V. Mathiowetz,et al.  Grip and pinch strength: normative data for adults. , 1985, Archives of physical medicine and rehabilitation.

[60]  G H Guyatt,et al.  Effect of encouragement on walking test performance. , 1984, Thorax.

[61]  M. Gardner,et al.  Statistical guidelines for contributors to medical journals. , 1983, British medical journal.

[62]  D. F. Rochester,et al.  Respiratory muscle failure. , 1983, The Medical clinics of North America.

[63]  S. Cajander,et al.  Muscle involvement in sarcoidosis. , 2009, Acta medica Scandinavica.

[64]  L. F. Black,et al.  Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .

[65]  L. Siltzbach,et al.  Muscle Involvement in Sarcoidosis: Asymptomatic, Myositis, and Myopathy , 1969 .

[66]  J. Scadding.  Prognosis of Intrathoracic Sarcoidosis in England , 1961, British medical journal.